This is a summary of the European public assessment report (EPAR) for Hetlioz. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Hetlioz. For practical information about using Hetlioz, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Hetlioz is indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in totally blind adults.
Therapeutic Area (MeSH)
N/AATC Code
N05CH
ATC Item
美洛托宁受体激动剂
Pharmacotherapeutic Group
Psycholeptics
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| tasimelteon | N/A | 他司美琼 |
EMA Name
Hetlioz
Medicine Name
Hetlioz
Aliases
N/ANo risk management plan link.
